| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Aug 17, 2022
KING OF PRUSSIA, PA CSL is on track to file for regulatory approvals next year and will present full data set at an upcoming scientific congress 17 Aug 2022 Global biotechnology leader CSL...
Jun 24, 2022CSL continues to provide medicines to patients around the world.CSL continues to provide medicines to patients around the world. 24 Jun 2022 Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues...
Jun 9, 2022Acclaimed Photographer Rankin and CSL Behring Team Up to Launch 'Portraits of Progress', an Exhibition Chronicling the Past, Present and Future of Life with HemophiliaRankin's first in-person U.S. exhibit in three years showcases portraits and personal stories highlighting the remarkable progress made in understanding and treating hemophilia and hopes for the future
-
May 24, 2022
-- If approved, etranacogene dezaparvovec would be the first gene therapy option for people living with hemophilia B -- This milestone underscores CSL Behring's promise to develop and deliver a...
-
Apr 28, 2022
The 500 million international units (IUs) will include product specifically manufactured for donation allowing for a longer shelf life and enabling more people around the world to access...
-
Mar 28, 2022
Marketing Authorization Application (MAA) for etranacogene dezaparvovec will be reviewed under accelerated assessment and has the potential to be the first gene therapy for patients living with...
Mar 2, 2022With 25,000 global employees, CSL is one of 500 Large Employers recognized across 25 industry sectorsForbes Magazine has named global biotechnology leader CSL among America's Best Employers for 2022. The annual rankings from Forbes and Statista, the world-leading statistics portal and industry...
-
Feb 4, 2022- Data from the largest gene therapy study in Hemophilia B to date shows that etranacogene dezaparvovec is statistically superior in reducing annualized bleeding rate compared to baseline FIX prophylactic therapy
Global biotherapeutics leader CSL Behring today announced positive long-term results from the Phase 3 HOPE-B clinical trial evaluating etranacogene dezaparvovec (EtranaDez), an investigational...
-
Jan 18, 2022Ad hoc release pursuant to Art. 53 LR, Switzerland
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited (ASX: CSL; USOTC: CSLLY), today published the offer prospectus regarding its public tender...
-
Dec 15, 2021
KING OF PRUSSIA, PA, USA – DECEMBER 15, 2021 – Global biotherapeutics leader CSL Behring today announced that the Committee for Medicinal Products for Human Use (CHMP), the chief scientific...